• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

123.76 -1.69 (-1.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,348,344
Open 125.85
Bid (Size) 123.44 (100)
Ask (Size) 123.65 (400)
Prev. Close 125.45
Today's Range 122.43 - 126.39
52wk Range 104.46 - 157.29
Shares Outstanding 1,253,809,440
Dividend Yield 2.65%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings?
June 18, 2026
Since December 2025, Gilead Sciences has been in a holding pattern, posting a small return of 2.7% while floating around $124.73. The stock also fell short o... 
Via StockStory
News headline image
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗
June 17, 2026
 
Via Benzinga

Performance

YTD
+1.8%
+1.8%
1 Month
-5.3%
-5.3%
3 Month
-9.8%
-9.8%
6 Month
-0.4%
-0.4%
1 Year
+14.1%
+14.1%

More News

Read More
News headline image
1 Cash-Producing Stock Worth Investigating and 2 We Brush Off
June 17, 2026
Via StockStory
News headline image
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
June 15, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
June 12, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
June 11, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial ↗
June 09, 2026
Via Benzinga
News headline image
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
June 08, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
June 08, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead ↗
June 08, 2026
Via MarketBeat
News headline image
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands ↗
June 05, 2026
Via MarketBeat
News headline image
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
June 05, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
June 04, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH? ↗
June 04, 2026
Via The Motley Fool
Topics ETFs
News headline image
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome ↗
June 02, 2026
Via Benzinga
News headline image
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
June 02, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
June 01, 2026
Via Benzinga
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
May 29, 2026
Via The Motley Fool
News headline image
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
May 27, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
If You Invested $1000 In Gilead Sciences Stock 15 Years Ago, You Would Have This Much Today ↗
May 26, 2026
Via Benzinga
News headline image
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference ↗
May 24, 2026
Via MarketBeat
News headline image
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
May 22, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
May 22, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
May 21, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
May 21, 2026
From Gilead Sciences, Inc.
Via Business Wire

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 123.76
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 06/18/26 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 155.17B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 155B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap